By Monica Heger

Whole-genome sequencing followed by ultra-deep targeted resequencing of B-cell chronic lymphocytic leukemia tumors throughout the course of treatment shows how patients' mutational profiles change in response to treatment and disease progression, according to an ongoing study.

Anna Schuh, a hematologist at the University of Oxford, reported preliminary results from the study at last week's Biology of Genomes meeting in Cold Spring Harbor, NY.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.